Skip to main content
. 2012 Mar 31;3(1):e52–e63.

Table 2.

Details of respondents’ fellowship training.

Feature No. (%)
Fellowship training (n = 148)
 Yes 115 (77.7)
 No 33 (22.3)
More than one fellowship (n = 103)
 Yes 15 (14.6)
 No 88 (85.4)
 Unknown 12 (N/A)
Length (months) of fellowship (n = 115)
 ≤11 10 (8.7)
 12 77 (67.0)
 13–23 24 (20.9)
 ≥24 4 (3.5)
Fellowship location (n = 115, multiple locations permitted)
 Ontario 48 (38.7)
 United States 29 (23.4)
 Europe 14 (11.3)
 British Columbia 11 (8.9)
 Alberta 11 (8.9)
 Australia 4 (3.2)
 Manitoba 2 (1.6)
 Quebec 2 (1.6)
 United Kingdom 1 (0.9)
 New Zealand 1 (0.9)
 Japan 1 (0.9)
Fellowship focus (n = 115, multiple selections permitted)
 Modern radiotherapy delivery technology 73 (63.5)
Specific cancer site 47 (41.8)
Stereotactic radiotherapy 38 (33.0)
Research 26 (22.6)
Brachytherapy 21 (18.3)
 Palliative care 5 (4.3)
 Medical education 3 (2.6)
 Proton and/or charged particle radiotherapy 2 (1.7)
Type of fellowship (n = 115; multiple selections permitted)
 Clinical only 4 (3.5)
 Mostly clinical, but some research 64 (55.7)
 Mostly research, but some clinical 35 (30.4)
 Research leading to Master’s or Ph.D. 13 (11.3)

n indicates numbers of respondents to each question

Radiotherapy delivery technology includes 3D conformal radiotherapy, intensity-modulated radiotherapy, helical tomotherapy, or volumetric modulated arc therapy

Stereotactic radiotherapy includes stereotactic radiosurgery or stereotactic body radiotherapy

Research includes clinical, imaging, population health, basic or translational research